Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients

NCT04259372 | Completed

• 1 other identifier: Tmet_AML
• Study Type: observational
• Target: 77
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objective of this study was to analyze the T cell metabolism and immune phenotype in AML patients during the course of the disease before and after allo-HCT.

Conditions

Acute Myeloid Leukemia

Outcome Measures

Primary Outcomes (2)

• T cell metabolism

  Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) determined by live-cell metabolic assay using the Seahorse Analyzer

  4 years

• T cell phenotype

  T cell cytokine and effector molecule production

  4 years

Secondary Outcomes (1)

• Metabolite abundance in serum

  4 years

Study Arms (3)

Primary Diagnosis

Analysis of patient blood at primary diagnosis of AML

Relapse

Analysis of patient blood at time point of relapse after allo-HCT

Remission

Analysis of patient blood during remission after allo-HCT

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with acute myeloid leukemia at primary diagnosis, at relapse after allo-HCT or in remission after allo-HCT.

You may qualify if:

• confirmed diagnosis of AML
• age ≥ 18 years
• peripheral blood sample available
• written informed consent
• ability to understand the nature of the study and the study related procedures and to comply with them

You may not qualify if:

• age \< 18 years
• lack of informed consent
• patients that cannot be classified in one of the 3 groups

Sponsors & Collaborators

• University of Freiburg: lead

Related Publications (3)

• Buck MD, O'Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, Qiu J, Kretz O, Braas D, van der Windt GJ, Chen Q, Huang SC, O'Neill CM, Edelson BT, Pearce EJ, Sesaki H, Huber TB, Rambold AS, Pearce EL. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell. 2016 Jun 30;166(1):63-76. doi: 10.1016/j.cell.2016.05.035. Epub 2016 Jun 9.

  PMID: 27293185 BACKGROUND

• Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27.

  PMID: 26321679 BACKGROUND

• Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A, Volin L, Gurman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V; EBMT Acute Leukemia Working Party. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007 Nov 1;25(31):4938-45. doi: 10.1200/JCO.2007.11.6053. Epub 2007 Oct 1.

  PMID: 17909197 BACKGROUND

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Robert Zeiser, Prof. Dr.

  Medical Center University of Freiburg

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of the Division of Tumor Immunology

Study Record Dates

• First Submitted: February 4, 2020
• First Posted: February 6, 2020
• Study Start: January 1, 2016
• Primary Completion: December 31, 2019
• Study Completion: December 31, 2019
• Last Updated: February 6, 2020

Record last verified: 2020-02

Data Sharing

• IPD Sharing: Will not share